PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32443710-0	2020	Thalidomide Reduces Vascular Endothelial Growth Factor Immunostaining in Canine Splenic Hemangiosarcoma.	Thalidomide	0-11	vascular endothelial growth factor A	Canis lupus familiaris	20-54	
32443710-2	2020	Recently it was demonstrated that thalidomide extends the survival time of dogs with HSA, potentially due to thalidomide-induced inhibition of vascular endothelial growth factor (VEGF) production by the neoplastic cells.	Thalidomide	34-45	vascular endothelial growth factor A	Canis lupus familiaris	143-177	
32443710-2	2020	Recently it was demonstrated that thalidomide extends the survival time of dogs with HSA, potentially due to thalidomide-induced inhibition of vascular endothelial growth factor (VEGF) production by the neoplastic cells.	Thalidomide	34-45	vascular endothelial growth factor A	Canis lupus familiaris	179-183	
32443710-2	2020	Recently it was demonstrated that thalidomide extends the survival time of dogs with HSA, potentially due to thalidomide-induced inhibition of vascular endothelial growth factor (VEGF) production by the neoplastic cells.	Thalidomide	109-120	vascular endothelial growth factor A	Canis lupus familiaris	143-177	
32443710-2	2020	Recently it was demonstrated that thalidomide extends the survival time of dogs with HSA, potentially due to thalidomide-induced inhibition of vascular endothelial growth factor (VEGF) production by the neoplastic cells.	Thalidomide	109-120	vascular endothelial growth factor A	Canis lupus familiaris	179-183	
32443710-3	2020	To investigate this, immunostaining was used to evaluate VEGF within HSA metastases that developed after thalidomide treatment.	Thalidomide	105-116	vascular endothelial growth factor A	Canis lupus familiaris	57-61	
32443710-7	2020	This supports the hypothesis that thalidomide prolongs survival time in dogs with HSA due to inhibition of VEGF production by the neoplastic cells.	Thalidomide	34-45	vascular endothelial growth factor A	Canis lupus familiaris	107-111	
32443710-8	2020	As VEGF remained visible within HSAs exposed to thalidomide, additional treatments to inhibit VEGF production may further prolong survival times of dogs with these common canine neoplasms.	Thalidomide	48-59	vascular endothelial growth factor A	Canis lupus familiaris	3-7	
32443710-8	2020	As VEGF remained visible within HSAs exposed to thalidomide, additional treatments to inhibit VEGF production may further prolong survival times of dogs with these common canine neoplasms.	Thalidomide	48-59	vascular endothelial growth factor A	Canis lupus familiaris	94-98